Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
53.90
-1.55 (-2.80%)
At close: Sep 9, 2025
-2.80%
Market Cap26.61B
Revenue (ttm)3.96B
Net Income (ttm)513.69M
Shares Out493.66M
EPS (ttm)2.21
PE Ratio24.34
Forward PEn/a
Dividend5.69 (10.57%)
Ex-Dividend DateJul 31, 2025
Volume572,248
Average Volume1,082,063
Open55.55
Previous Close55.45
Day's Range53.10 - 56.00
52-Week Range47.44 - 62.30
Beta0.06
RSI43.82
Earnings DateAug 29, 2025

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of... [Read more]

Sector Healthcare
Founded 2001
Employees 4,861
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6887
Full Company Profile

Financial Performance

In 2024, Sunshine Lake Pharma's revenue was 3.72 billion, a decrease of -40.84% compared to the previous year's 6.29 billion. Earnings were 482.71 million, a decrease of -75.78%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.